The NCGM’s Center Hospital and several other hospitals in Tokyo, Osaka and Nagoya have been asking recovered COVID-19 patients to donate their plasma samples if an initial blood test confirms the presence of high levels of antibodies
Scientists reveal 76 percent of critically ill trial participants treated with convalescent plasma are recovering, with almost half now discharged from hospital.
Kedrion Biopharma, an Italian biotech company, has started the development of a plasma-derived therapy for treating the COVID-19 virus that could make it available to patients.
Spanish healthcare company Grifols has teamed up with the US Government agencies, including the Biomedical Advanced Research Development Authority (BARDA) ...